标题
Olaparib for metastatic breast cancer in a patient with a germline PALB2 variant
作者
关键词
-
出版物
npj Breast Cancer
Volume 6, Issue 1, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2020-07-24
DOI
10.1038/s41523-020-00174-9
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Dramatic response to PARP inhibition in a PALB2-mutated breast cancer: moving beyond BRCA
- (2020) T. Grellety et al. ANNALS OF ONCOLOGY
- OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer
- (2019) M E Robson et al. ANNALS OF ONCOLOGY
- Talazoparib beyond BRCA: A phase II trial of talazoparib monotherapy in BRCA1 and BRCA2 wild-type patients with advanced HER2-negative breast cancer or other solid tumors with a mutation in homologous recombination (HR) pathway genes.
- (2019) Joshua James Gruber et al. JOURNAL OF CLINICAL ONCOLOGY
- GeparOLA: A randomized phase II trial to assess the efficacy of paclitaxel and olaparib in comparison to paclitaxel/carboplatin followed by epirubicin/cyclophosphamide as neoadjuvant chemotherapy in patients (pts) with HER2-negative early breast cancer (BC) and homologous recombination deficiency (HRD).
- (2019) Peter A. Fasching et al. JOURNAL OF CLINICAL ONCOLOGY
- A synonymous germline variant PALB2 c.18G>T (p.Gly6=) disrupts normal splicing in a family with pancreatic and breast cancers
- (2018) Ciyu Yang et al. BREAST CANCER RESEARCH AND TREATMENT
- Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
- (2018) Jennifer K. Litton et al. NEW ENGLAND JOURNAL OF MEDICINE
- Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response—final results from GeparSixto
- (2018) S Loibl et al. ANNALS OF ONCOLOGY
- A Phase II Study of Talazoparib After Platinum or Cytotoxic Nonplatinum Regimens in Patients With Advanced Breast Cancer and Germline BRCA1/2 Mutations (ABRAZO)
- (2018) Nicholas C. Turner et al. CLINICAL CANCER RESEARCH
- Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
- (2018) Kathleen Moore et al. NEW ENGLAND JOURNAL OF MEDICINE
- HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures
- (2017) Helen Davies et al. NATURE MEDICINE
- Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
- (2017) Mark Robson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Use of poly ADP-ribose polymerase [PARP] inhibitors in cancer cells bearing DDR defects: the rationale for their inclusion in the clinic
- (2016) Aniello Cerrato et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Olaparib Monotherapy in Patients With Advanced Cancer and a GermlineBRCA1/2Mutation
- (2015) Bella Kaufman et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical outcomes in women with breast cancer and a PALB2 mutation: a prospective cohort analysis
- (2015) Cezary Cybulski et al. LANCET ONCOLOGY
- DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
- (2015) Joaquin Mateo et al. NEW ENGLAND JOURNAL OF MEDICINE
- ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP Inhibitors
- (2015) J. Shen et al. Cancer Discovery
- Breast-Cancer Risk in Families with Mutations in PALB2
- (2014) Antonis C. Antoniou et al. NEW ENGLAND JOURNAL OF MEDICINE
- A novel germline PALB2 deletion in Polish breast and ovarian cancer patients
- (2010) Agnieszka Dansonka-Mieszkowska et al. BMC Medical Genetics
- Cooperation of breast cancer proteins PALB2 and piccolo BRCA2 in stimulating homologous recombination
- (2010) Rémi Buisson et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- The Breast Cancer Susceptibility Mutation PALB2 1592delT Is Associated with an Aggressive Tumor Phenotype
- (2009) T. Heikkinen et al. CLINICAL CANCER RESEARCH
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More